The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).
 
Kristen Carroll
No Relationships to Disclose
 
Michael C. Burns
No Relationships to Disclose
 
Ryan Jones
Employment - Tempus; Tempus; Tempus; Tempus
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".; Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".; Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".; Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Kirsten Bell Burdett
Employment - QuintilesIMS; QuintilesIMS; QuintilesIMS; QuintilesIMS
 
Guang-Yu Yang
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AXIO Research; AXIO Research; AXIO Research; AXIO Research; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; inVentiv Health; inVentiv Health; inVentiv Health; inVentiv Health; Lilly; Lilly; Lilly; Lilly; LSK BioPharma; LSK BioPharma; LSK BioPharma; LSK BioPharma; Merck; Merck; Merck; Merck; NCCN; NCCN; NCCN; NCCN; Purdue Pharma; Purdue Pharma; Purdue Pharma; Purdue Pharma; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Terumo; Terumo; Terumo; Terumo; TheraBionic; TheraBionic; TheraBionic; TheraBionic
Research Funding - Acerta Pharma; Acerta Pharma; Acerta Pharma; Acerta Pharma; advanced accelerator applications (Inst); advanced accelerator applications (Inst); advanced accelerator applications (Inst); advanced accelerator applications (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); MedImmune; MedImmune; MedImmune; MedImmune; Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Xencor; Xencor; Xencor; Xencor
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Guardant Health; Guardant Health; Guardant Health; Guardant Health; guerbet; guerbet; guerbet; guerbet; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Sanofi; Sanofi; Sanofi; Sanofi; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; TRM Oncology; TRM Oncology; TRM Oncology; TRM Oncology
 
Devalingam Mahalingam
Honoraria - Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Genentech; Genentech; Genentech; Genentech
Research Funding - Merck; Merck; Merck; Merck; Merck; Merck; Merck; Merck; Oncolytics; Oncolytics; Oncolytics; Oncolytics; Oncolytics; Oncolytics; Oncolytics; Oncolytics
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Eisai; Eisai; Eisai; Eisai; Genentech; Genentech; Genentech; Genentech